Reading CNTN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CNTN free→Reading CNTN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CNTN free→
NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is elevated, and the sector backdrop is a headwind, which may impact the company's prospects. If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting CNTN and other Healthcare names. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $3.30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.26x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
23 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company has announced a $50 million share repurchase program to enhance shareholder value.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$353.
How much price usually moves either way.
On a bad day, this stock has moved -$1,065.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,121.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CNTN yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. 2026 Share Repurchase Program On June 11, 2026, the Board of Directors the Company approved a share repurchase program (the “ 2026 Share Repurchase Program ”) providing for the repurchase of up to $50 million of the Company’s outstanding shares of Common Stock. Under the 2026 Share Repurchase Program, the Company is authorized to repurchase shares of Common Stock through open market purchases, privately-negotiated transactions, or otherwise in accordance with applicable federal…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus peers.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CNTN CANTON STRATEGIC HOLDINGS INC | — | — | elevated |
Not investment advice. As of 2026-06-16.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Newly stated in 2026-Q2. The company announced a $50 million share repurchase program, but there is no financial data yet to assess its impact. This is a new initiative aimed at capital allocation.
“The Board approved a share repurchase program for up to $50 million...”
The company received a notification regarding noncompliance with Nasdaq Listing Rule 5605 and must address this issue.
Newly stated in 2026-Q1. The company is addressing a compliance issue with Nasdaq Listing Rule 5605. There is no financial data provided to evaluate progress on this regulatory priority.
“The company received a notification letter from Nasdaq regarding noncompliance...”
The company continues to face significant operating losses and must manage these effectively.
Stated in 4 of last 4 quarters. Operating income was negative, with a loss of $36.9 million in 2026-Q1, worsening from $1.9 million in 2025-Q2. The trajectory shows increasing operating losses, indicating limited progress in managing costs.
“Operating income was negative, with a loss of $36.9 million...”
“Operating income was negative, with a loss of $13.6 million...”
“Operating income was negative, with a loss of $2.1 million...”
“Operating income was negative, with a loss of $1.9 million...”
Regulation FD Disclosure. On June 16, 2026, Canton Strategic Holdings, Inc. (the “ Company ”) issued a press release announcing the 2026 Share Repurchase Program (as defined below), a copy of which is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, will not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and will not be incorporated by reference into any filing under the S…
Material Definitive Agreement On March 3, 2026, Canton Strategic Holdings, Inc. (the “ Company ”), entered into an amended and restated sales agreement (the “ Sales Agreement ”) with Clear Street LLC (“ Clear Street ”) and Virtu Americas LLC (“ Virtu ”, and together with Clear Street, the “ Sales Agents ”), relating to the sale of shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”). The Sales Agreement amends and restates the ATM Sales Agreement, dated as…
Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 5, 2026, the Board of Directors (the “ Board ”) of Tharimmune, Inc. (the “ Company ”) appointed Angela Dominy Radkowski, age 37, as Chief Operating Officer of the Company, effective February 5, 2026 (the “ Effective Date ”). Prior to her appointment, Ms. Radkowski served as Operations Strategy Lead and Chief of Staff to the Chief Operat…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 9, 2026, Tharimmune, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605 (“Rule 5605”), which requires, among other things, that a majority of the Board of Directors of the Company (the “Board”) be comprised of independent directors. As previously disclosed, Nancy Davis and Sanam Parikh resign…